Michael Wang | Head, Global Investment & Business Development, China Grandpharma (CGP)
Michael Wang, Head for Business Development at China Grandpharma (CGP), has been with the company and its affiliates since 2001. While implementing the key corporate development strategies of“innovation”and “going global”for the past few years, many achievements have been made, including Cardiovovum & Conavi in cardiovascular areas, Sepsis program with ANU and Parainfluenza with GU in infections, Dry Eye project with BRIM in Taiwan & Pterygium project with Cloudbreak in the U.S. in ophthalmology, and very recently, an mRNA platform project with eTheRNA in Belgium in oncology and infections. Dr. Wang had a medical education, had served in GSK and other multinational companies prior to joining CGP and has over 30 years of pharmaceutical industry experiences in China.
About China Grandpharma
As an innovative and fast-growing pharma company headquartered in China and listed in Hong Kong (0512.hk), the strategic business units of China Grand Pharmaceutical and Healthcare Holdings Limited are oncology, cardiology, respiratory, ophthalmology, among others. Business operations are mainly in China, but oncology and cardiology have established global presence. Research centers are set up in Wuhan, Nanjing, Boston, Belgium and Sydney to facilitate growing needs. The company is constantly looking for innovative pharma and medtech projects in the above areas to reinforce the SBU. In 2020, we recorded a revenue of about US$800 million with a market cap of US$3 billion.
Sponsors & Partners
| Powered by: Hyphen Projects | Connect with us | Access Biotech China Newsletter | ||
| Contact Us Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
| Subscribe
|
© Copyright 2021 by Hyphen Projects